Botox / Dysport / Xeomin

M.D. Claiborne & Associates, L.L.C. - Dermatology Specialists

Presently there are three different injectable products approved by the FDA for treatment of facial wrinkles – Botox®, Dysport®, and Xeomin®. These products are the most common cosmetic procedure in the country and are one of the most effective means to reverse facial aging. Known as neuromodulators, these products weaken the ability of facial muscles to contract, effectively giving patients a more relaxed look. Each neuromodulator treatment is customized to a patient’s face and cosmetic goals. Potential cosmetic areas that can be treated include:

  • Forehead lines
  • Glabellar lines (lines between the eyebrows, or “11” lines)
  • Crow’s feet (lines around the eyes)
  • Gummy smile
  • Lines around the mouth
  • Excessive lines on the neck
  • Overly prominent jaw muscle

Neuromodulator injections are a quick in office procedure with no downtime. Prior to treatment, Dr. Claiborne meets with patients to discuss whether they are a candidate for neuromodulator injections. Patients that are pregnant or have a history of a neuromuscular disease would not be candidates for neuromodulators. Optimal facial rejuvenation outcomes often result from combination therapy with dermal fillers, lasers, and/or chemical peels.
BTXC-colorIn 2002, Botox was the first product approved by the FDA for temporary improvement in the glabellar lines (the wrinkles between the eyebrows). Since that time, it has also gained FDA approvals for the treatment of migraines, hyperhidrosis (excessive underarm sweating), blepharospasm, and eye misalignment. In 2013, Botox was approved for the treatment of crow’s feet.

Before Botox

Before Botox

After Botox

After Botox

Crow's Feet Before

Crow’s Feet Before Botox

Crow’s Feet After Botox

Dysport is a competitor to Botox and was FDA approved for glabellar lines in 2009. Some studies have shown that it can take effect quicker than Botox and may last a longer period before wearing off, but individual results vary.dysport_logo_ISI_rgb

Before Dysport

Before Dysport

After Dysport

After Dysport

 

Xeomin was the third neuromodulator to market for treatment of glabellar frown lines, and was FDA approved in 2011.